During the past 12 months, UroGen Pharma's average Revenue per Share Growth Rate was 1.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 74.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 247.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 9 years, the highest 3-Year average Revenue per Share Growth Rate of UroGen Pharma was 1313.10% per year. The lowest was -91.20% per year. And the median was 74.30% per year.
Competitive Comparison of UroGen Pharma's 3-Year Revenue Growth Rate
For the Biotechnology subindustry, UroGen Pharma's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UroGen Pharma's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UroGen Pharma's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where UroGen Pharma's 3-Year Revenue Growth Rate falls into.
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
UroGen Pharma 3-Year Revenue Growth Rate Related Terms
Thank you for viewing the detailed overview of UroGen Pharma's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
UroGen Pharma (UroGen Pharma) Business Description
UroGen Pharma Ltd is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative solutions that treat urothelial and specialty cancers. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
URGN has been successfully added to your